International Wex Technologies (WXI): Peru Grants Authorization; Planning Clinical Trial Of Tetrodonin
10/19/2005 5:10:37 PM
International Wex Technologies Inc. (the "Company") is pleased to announce that through its subsidiary, Acro Pharm Corp. (formerly GlobalMed Corp.), and its distributor in Peru, a Sanitary Registry Authorization has been obtained for our product Tetrodonin(TM) (a product derived from our platform drug).
This allows the Company to sell our product in Peru. Prior to sales, our distribution agreement states that clinical trials will be undertaken in that country. A clinical trial in Peru is now in the planning. The trial will be a double-blind, randomized, placebo-controlled, fixed repeated-dose efficacy and safety study to determine the efficacy of Tetrodonin(TM) in decreasing drug use and the severity of drug withdrawal symptoms and to assess its safety and tolerability for therapeutic use in drug-dependent subjects.
Acro Pharm Corp. will coordinate the project with the Peruvian distributor to conduct the clinical trial. The timeline for commencement of this trial has not yet been established. Further details will be announced as the project progresses.
comments powered by